Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q2 EPS of ($0.19), $0.02 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $10 million versus the consensus estimate of $7.75 million.

Cash, cash equivalents and marketable securities were $88.2 million at June 30, 2017, compared with $77.0 million at December 31, 2016, and a projected year-end 2017 balance of between $55 million and $65 million. The company believes its financial resources, including a $7.0 million license option exercise payment received in July 2017 and anticipated expense reimbursements related to the Novartis agreement, are sufficient to maintain operations and ongoing emricasan clinical development activities through the end of 2019, as well as to fund anticipated pipeline expansion activities.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.